(Q58803510)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

title

Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

1 reference

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

Vito Di Marco

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

Riccardo Volpes

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

author name string

O Lo Iacono

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

P Almasio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

R Bruno

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

C Cammà

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

L Pagliaro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

publication date

1 May 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

page(s)

539-546

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

18 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant ?-interferon for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Histologically advanced chronic hepatitis C treated with recombinant alpha-interferon: a randomized placebo-controlled double-blind cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Antiviral therapy of hepatitis C--present and future

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Raising the dose of interferon does not improve the response in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Low-dose interferon in chronic hepatitis non-A/non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

A proposed system for the nomenclature of hepatitis C viral genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Hepatitis C virus genotypes in chronic hepatitis and response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Relative frequency of nonneutralizing antibodies to interferon (IFN) in hepatitis patients treated with different IFN-alpha preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Detection of hepatitis C viral sequences in formalin-fixed, paraffin-embedded liver tissue: effect of interferon alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Long-term follow-up of patients with chronic hepatitis C treated with α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

Long-term carriage of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980138-3

7 January 2021

10.1016/S0168-8278(96)80138-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8773908%20AND%20SRC:MED&resulttype=core&format=json

18 October 2019

1 reference